Document Detail

Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model.
MedLine Citation:
PMID:  11089529     Owner:  NLM     Status:  MEDLINE    
Brief coronary occlusion followed by reperfusion leads to reversible myocardial dysfunction (stunning) which can induce irreversible damage of other organ systems. We studied the effects of pretreatment with recombinant human GH (rhGH) and the GH-secretagogue GHRP-2 on myocardial stunning in a blood-perfused isolated rabbit heart model. In a first set of experiments, effects of bolus rhGH administration (3.5 mg/kg) (n = 5) into the aortic root of unpretreated animals were compared with those of saline (n = 6). In a second set, animals were pretreated for 14 days with SC rhGH 3.5 mg/kg x day (n = 9) or 160 microg/kg x day GHRP-2 (n = 8) in two divided doses. Body weight and plasma concentrations of rhGH, rabbit GH (rGH) and IGF-I were determined before and at the end of 14 days pretreatment. Hearts were excised and submitted to 15 min ischemia followed by 80 min reperfusion, after which postischemic recovery was compared with nonischemic hearts mounted into the same system. At study end, all hearts were snap-frozen to examine markers of apoptosis. Circulating levels of rabbit GH (rGH) remained identical in all animals. Pretreatment with rhGH for 14 days induced a 142 +/- 116% rise of serum IGF-I vs. 8 +/- 15% with GHRP-2 (P < 0.001) and increased body weight with 6.8 +/- 2.5% vs. 3.4 +/- 3.3% with GHRP-2 (P = 0.01). A bolus injection of rhGH did not alter myocardial function compared with saline allowing data from these experiments to be pooled into one ischemic control group for further analysis of the effect of pretreatment. No difference in postischemic recovery of left ventricular systolic function among the unpretreated, rhGH pretreated and GHRP-2 pretreated hearts was apparent. At the end of reperfusion, a 3-fold higher end-diastolic pressure (EDP) persisted in the unpretreated and rhGH pretreated hearts compared with the nonischemic hearts. In the GHRP-2 pretreated hearts, EDP decreased to half the pressure observed in unpretreated and rhGH pretreated hearts (all P < or = 0.02), a level which was indistinguishable from that in the non-ischemic hearts, suggesting full postischemic recovery of diastolic function. There were no signs of increased apoptosis in the experimental groups. In conclusion, 14 days pretreatment with GHRP-2, but not rhGH, protected selectively against the diastolic dysfunction of myocardial stunning in this model. This observation may open perspectives for GH-secretagogues as cardioprotective agents.
F Weekers; E Van Herck; J Isgaard; G Van den Berghe
Related Documents :
16434759 - Role of erk1/2, p70s6k, and enos in isoflurane-induced cardioprotection during early re...
21744079 - Phase i study of sunitinib and irinotecan for patients with recurrent malignant glioma.
22001539 - Improvement of low bioavailability of a novel factor xa inhibitor through formulation o...
21612749 - Comparative pharmacokinetics and bioequivalence of two tablet formulations of 2 mg risp...
7303069 - Platelet embolism in rabbit brain.
12967629 - Second window of protection following myocardial preconditioning: an essential role for...
9494769 - Oral mifepristone 600 mg and vaginal gemeprost for mid-trimester induction of abortion....
23845699 - A phase i trial of aminolevulinic acid-photodynamic therapy for treatment of oral leuko...
6745169 - Liposome-entrapped diethylstilbestrol effect on prostate gland and plasma testosterone ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Endocrinology     Volume:  141     ISSN:  0013-7227     ISO Abbreviation:  Endocrinology     Publication Date:  2000 Nov 
Date Detail:
Created Date:  2000-11-29     Completed Date:  2000-12-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375040     Medline TA:  Endocrinology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  3993-9     Citation Subset:  AIM; IM    
Department of Intensive Care Medicine and Center for Experimental Surgery & Anaesthesiology, Catholic University of Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apoptosis / drug effects
Blood Pressure
Body Weight
Coronary Circulation
Disease Models, Animal*
Growth Hormone / blood
Human Growth Hormone / pharmacology*
Insulin-Like Growth Factor I / metabolism
Myocardial Stunning / physiopathology*
Oligopeptides / pharmacology*
Ventricular Function, Left
Reg. No./Substance:
0/Oligopeptides; 0/growth hormone-releasing peptide-2; 12629-01-5/Human Growth Hormone; 67763-96-6/Insulin-Like Growth Factor I; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Concerted regulation of steroidogenic acute regulatory gene expression by luteinizing hormone and in...
Next Document:  Diametric effects of bacterial endotoxin lipopolysaccharide on adrenal and Leydig cell steroidogenic...